Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Non-Randomized, Open-Label, Repeat-Dose, Single Center Study Utilizing a Master Protocol to Investigate the Safety and Tolerability of Multiple Study Interventions in Advanced Therapy Naïve Participants With Moderate to Severe Ulcerative Colitis

NCT07747467 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07747467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07747467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Non-Randomized, Open-Label, Repeat-Dose, Single Center Study Utilizing a Master Protocol to Investigate the Safety and Tolerability of Multiple Study Interventions in Advanced Therapy Naïve Participants With Moderate to Severe Ulcerative Colitis
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 10, 2026
Completion date
December 4, 2028
Enrollment
16 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colitis, ulcerative